Prostacyclin, Atherothrombosis and Diabetes Mellitus: Physiologic and Clinical Considerations.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Current molecular medicine

• Publication date

  2016-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.2174/1566524016666160316150728PMID 26980701
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes

  2014cited by this paper
• 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8).

  2014cited by this paper
• Effect of single nucleotide polymorphisms of the prostacyclin receptor gene on platelet activation in Japanese healthy subjects and patients with cerebral infarction.

  2013cited by this paper
• Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials

  2013cited by this paper
• Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part I

  2013cited by this paper
• LC-MS/MS Confirms That COX-1 Drives Vascular Prostacyclin Whilst Gene Expression Pattern Reveals Non-Vascular Sites of COX-2 Expression

  2013cited by this paper
• Reduced expression of prostacyclin synthase and nitric oxide synthase in subcutaneous arteries of type 2 diabetic patients.

  2013cited by this paper
• Cyclooxygenase-1, not cyclooxygenase-2, is responsible for physiological production of prostacyclin in the cardiovascular system

  2012cited by this paper
• Antithrombotic therapy in peripheral artery disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

  2012cited by this paper
• Involvement of cyclo‐oxygenase‐1‐mediated prostacyclin synthesis in the vasoconstrictor activity evoked by ACh in mouse arteries

  2012cited by this paper
• Adherence to drugs that prevent cardiovascular disease: meta-analysis on 376,162 patients.

  2012cited by this paper
• Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis

  2011cited by this paper
• Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: a guideline for healthcare professionals from the american heart association/american stroke association.

  2011cited by this paper
• Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies

  2010cited by this paper
• Aspirin for Primary Prevention of Cardiovascular Events in People With Diabetes

  2010cited by this paper
• Dominant Negative Actions of Human Prostacyclin Receptor Variant Through Dimerization: Implications for Cardiovascular Disease

  2010cited by this paper
• Venous thromboembolism: a public health concern.

  2010cited by this paper
• Comprehensive Biochemical Analysis of Rare Prostacyclin Receptor Variants

  2010cited by this paper
• Selective cyclooxygenase-2 inhibition reduces endothelial dysfunction and improves inflammatory status in patients with intermittent claudication.

  2009cited by this paper
• Cardiovascular Safety of the Cyclooxygenase-2 Selective Inhibitors Parecoxib and Valdecoxib in the Postoperative Setting: An Analysis of Integrated Data

  2009cited by this paper
• Endothelial dysfunction in mice with streptozotocin-induced type 1 diabetes is opposed by compensatory overexpression of cyclooxygenase-2 in the vasculature.

  2009cited by this paper
• Heart Disease and Stroke Statistics—2015 Update: A Report From the American Heart Association

  2009cited by this paper
• Acceleration of Cardiovascular Disease by a Dysfunctional Prostacyclin Receptor Mutation: Potential Implications for Cyclooxygenase-2 Inhibition

  2008cited by this paper
• Differential association between human prostacyclin receptor polymorphisms and the development of venous thrombosis and intimal hyperplasia: a clinical biomarker study

  2008cited by this paper
• Gastric mucosal defense and cytoprotection: bench to bedside.

  2008cited by this paper
• Cardioprotective prostacyclin signaling in vascular smooth muscle.

  2007cited by this paper
• Pharmacodynamic of cyclooxygenase inhibitors in humans.

  2007cited by this paper
• Ethnic-specific prevalence of peripheral arterial disease in the United States.

  2007cited by this paper
• Prostacyclin agonist with thromboxane synthase inhibitory activity (ONO-1301) attenuates bleomycin-induced pulmonary fibrosis in mice.

  2006cited by this paper
• Risk of acute myocardial infarction with nonselective non-steroidal anti-inflammatory drugs: a meta-analysis

  2006cited by this paper
• Clinical trial design and patient demographics of the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) study program: cardiovascular outcomes with etoricoxib versus diclofenac in patients with osteoarthritis and rheumatoid arthritis.

  2006cited by this paper
• Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison.

  2006cited by this paper
• The ever growing story of cyclo-oxygenase inhibition.

  2006cited by this paper
• Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery.

  2005cited by this paper
• Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial.

  2005cited by this paper
• Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities.

  2005cited by this paper
• Coxibs and cardiovascular disease.

  2004cited by this paper
• Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines

  2004cited by this paper
• COX-2-Derived Prostacyclin Confers Atheroprotection on Female Mice

  2004cited by this paper
• Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial.

  2004cited by this paper
• Treatment of pulmonary arterial hypertension.

  2004cited by this paper
• Risk of cardiovascular events and rofecoxib: cumulative meta-analysis.

  2004cited by this paper
• COX-2 and beyond: approaches to prostaglandin inhibition in human disease

  2003cited by this paper
• High Glucose Causes Upregulation of Cyclooxygenase-2 and Alters Prostanoid Profile in Human Endothelial Cells: Role of Protein Kinase C and Reactive Oxygen Species

  2003cited by this paper
• Effects of TRA‐418, a novel TP‐receptor antagonist, and IP‐receptor agonist, on human platelet activation and aggregation

  2003cited by this paper
• Selective COX-2 Inhibition Improves Endothelial Function in Coronary Artery Disease

  2003cited by this paper
• Short- and Long-Term COX-2 Inhibition Reverses Endothelial Dysfunction in Patients With Hypertension

  2003cited by this paper
• Carotid Atherosclerosis in Type 2 Diabetes Mellitus: Potential Role of Endothelin-1, Lipoperoxides, and Prostacyclin

  2002cited by this paper
• A novel pathway of prostacyclin signaling-hanging out with nuclear receptors.

  2002cited by this paper
• Role of Prostacyclin in the Cardiovascular Response to Thromboxane A2

  2002cited by this paper
• Differential effects of stable prostacyclin analogs on smooth muscle proliferation and cyclic AMP generation in human pulmonary artery.

  2002cited by this paper
• Impaired Receptor Binding and Activation Associated with a Human Prostacyclin Receptor Polymorphism*

  2002cited by this paper
• Relationship between thromboxane/prostacyclin ratio and diabetic vascular complications.

  2001cited by this paper
• Risk of cardiovascular events associated with selective COX-2 inhibitors.

  2001cited by this paper
• Roles of Prostaglandin I2 and Thromboxane A2 in Cardiac Ischemia-Reperfusion Injury: A Study Using Mice Lacking Their Respective Receptors

  2001cited by this paper
• Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study.

  2000cited by this paper
• Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group.

  2000cited by this paper
• Cyclooxygenases: structural, cellular, and molecular biology.

  2000cited by this paper
• Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2.

  1999cited by this paper
• Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids.

  1999cited by this paper
• Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension.

  1999cited by this paper
• Experimental models used to investigate the differential inhibition of cyclooxygenase-1 and cyclooxygenase-2 by non-steroidal anti-inflammatory drugs

  1998cited by this paper
• Altered pain perception and inflammatory response in mice lacking prostacyclin receptor

  1997cited by this paper
• A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension.

  1996cited by this paper
• International Union of Pharmacology classification of prostanoid receptors: properties, distribution, and structure of the receptors and their subtypes.

  1994cited by this paper
• Biological actions of prostacyclin and its pharmacological use in platelet studies.

  1985cited by this paper
• Clinical pharmacology and potential of prostacyclin.

  1983cited by this paper
• Decreased vascular prostacyclin (PGI2) in diabetic rats. Stimulation of PGI2 release in normal and diabetic rats by the antithrombotic compound Bay g 6575.

  1980cited by this paper
• Vascular prostacyclin may be reduced in diabetes in man.

  1979cited by this paper
• Decreased vascular prostacyclin in juvenile-onset diabetes.

  1979cited by this paper
• Arachidonic acid metabolites and the interactions between platelets and blood-vessel walls.

  1979cited by this paper
• Decreased vascular prostacyclin in experimental diabetes.

  1978cited by this paper
• Human arterial and venous tissues generate prostacyclin (prostaglandin x), a potent inhibitor of platelet aggregation.

  1977cited by this paper
• An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation

  1976cited by this paper

• Platelets in Renal Disease

  2023cites this paper
• Flavonoids extract from Rosa roxburghii fruit ameliorates carrageenan-induced thrombosis in mice

  2023cites this paper
• Research on Potential Network Markers and Signaling Pathways in Type 2 Diabetes Based on Conditional Cell-Specific Network

  2022cites this paper
• Possible Role of Mitochondrial DNA Mutations in Chronification of Inflammation: Focus on Atherosclerosis

  2020cites this paper
• Eicosanoid blood vessel regulation in physiological and pathological states.

  2020cites this paper
• Highlights from the 2019 International Aspirin Foundation Scientific Conference, Rome, 28 June 2019: benefits and risks of antithrombotic therapy for cardiovascular disease prevention

  2020cites this paper
• Cardiovascular risk of non-steroidal anti-inflammatory drugs.

  2019cites this paper
• DIABETES MELLITUS AND PULMONARY CIRCULATION (PART 2)

  2019cites this paper
• Creating a mouse model resistant to induced ischemic stroke and cardiovascular damage

  2018cites this paper
• Diabetes modifies the role of prostanoids and potassium channels which regulate the hypereactivity of the rabbit renal artery to BNP

  2018cites this paper
• A regulatory insertion-deletion polymorphism in the FADS gene cluster influences PUFA and lipid profiles among Chinese adults: a population-based study.

  2018cites this paper
• Highlighting Diabetes Mellitus: The Epidemic Continues.

  2018cites this paper
• Hydroxyeicosatetraenoic acids in patients with pancreatic cancer: a preliminary report.

  2018cites this paper
• Cyclooxygenase-2 mediates puerarin to inhibit the invasion and metastasis of lung cancer A549 cells

  2017cites this paper
• Gallic acid improves endothelium‐dependent vasodilatory response to histamine in the mesenteric vascular bed of diabetic rats

  2017cites this paper
• Mechanisms involved in the increased sensitivity of the rabbit basilar artery to atrial natriuretic peptide in diabetes

  2017cites this paper
• Schmidt Highlighting Diabetes Mellitus e 3 Diabetes Mellitus : Tissue Damage and Healing and Therapeutic Opportunities

  2017cites this paper
• World Journal of Methodology

  year unknowncites this paper